VRTX Stock Price Today (October 2026) — Vertex Pharmaceuticals Incorporated Analysis & Key Metrics 2026-10-20
Vertex Pharmaceuticals Incorporated (VRTX) is trading at $514.65, up 2.53% today (as of October 2026). The stock continues to show mixed signals with a short-term dip within a broader uptrend, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $571.46 (11.0% upside).
- Volatility is moderate (26.53% annualized), implying notable price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (12.50% YoY) alongside competitive pressures in the Biotechnology space.
VRTX Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Vertex Pharmaceuticals Incorporated - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $124.57B
P/E Ratio
Forward P/E: 24.75
Revenue Growth
Year over Year
Analyst Target
+11.0% upside potential
Key Investor Questions About VRTX
What investors need to know before buying
Based on current market data, VRTX presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 54.87)
- Fundamentals say: Looking solid (debt and growth supportive)
VRTX's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for VRTX investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $1.98B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, VRTX stock traded between $403.16 and $560.25 and currently trades in the middle of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 26.53% annualized volatility and β=0.61, the stock exhibits low sensitivity to market moves—making VRTX suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Vertex Appoints Daniel Brennan to its Board of Directors
Vertex Pharmaceuticals (VRTX) Sees $11.6 Million in Net ETF Buying on Thursday
What Vertex Pharmaceuticals (VRTX)'s Pancreas Recovery Data Means For Shareholders
Latest TickZen Insights
All insights →No TickZen article on VRTX yet. Our newest analysis:
Explore More Analysis for VRTX
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 2, 2026 (after the close, usually)
Frequently Asked Questions
Common investor questions about Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated (VRTX) is currently trading at $514.65. The RSI (14-day) is at 54.9, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $571.46 implies 11.0% upside from current levels. Volatility is moderate at 26.5% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Vertex Pharmaceuticals Incorporated (VRTX): The trailing P/E ratio is 30.10, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 24.75, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.90, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 6.50. Price-to-Sales is 10.46. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 28 analysts covering VRTX, the consensus price target is $571.46. This represents a 11.0% upside from the current price of $514.65. The range spans from a low target of $350.00 to a high target of $667.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Vertex Pharmaceuticals Incorporated (VRTX) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Vertex Pharmaceuticals Incorporated (VRTX) investors include: 1. Moderate volatility (26.5% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Vertex Pharmaceuticals Incorporated's (VRTX) current debt and financial health profile: Total debt stands at $1.98B. The debt-to-equity ratio is 0.10x, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 3.19, indicating strong short-term liquidity. The quick ratio is 2.54. The company holds $7.85B in cash and equivalents. Free cash flow is positive at $2.63B, providing a cushion for debt servicing and shareholder returns.